Zobrazeno 1 - 10
of 524
pro vyhledávání: '"Ma Khamashta"'
Autor:
Chee-Seng Yee, Athiveeraramapandian Prabu, L. S. Teh, Ma. Khamashta, S. Tosounidou, Peter Lanyon, N McHugh, Vernon T. Farewell, D. Isenberg, Ian N. Bruce, R. Stevens, Christopher J Edwards, Mohammed Akil, Yasmeen Ahmad, B Griffiths, Caroline Gordon, Anisur Rahman
Publikováno v:
Annals of the Rheumatic Diseases. 80:266.2-267
Background:There had been very limited data on the development of damage and mortality in an inception cohort of SLE patients who were recruited very soon after diagnosis.Objectives:This study aimed to analyse the development of damage and death in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8ea90be4b6f3c7782a1ab2e227f3c75
https://doi.org/10.1136/annrheumdis-2021-eular.8
https://doi.org/10.1136/annrheumdis-2021-eular.8
Publikováno v:
Fetal and Maternal Medicine Review. 22:265-286
The Antiphospholipid syndrome (APS) is one of the current hot topics embracing rheumatology and obstetrics.The first clinical description of APS was in 1983. Venous or arterial thrombosis, abortion and cerebral manifestations along with circulating a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48fe1ee5be9b189d1ed6c820119a48b5
https://doi.org/10.1017/s0965539511000131
https://doi.org/10.1017/s0965539511000131
Publikováno v:
La Revue de Médecine Interne. 28:103-107
Purpose The antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis, and pregnancy morbidity in association with antiphospholipid antibodies. Since its classical description 22 years ago, the clinical spectrum of APS has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d0d292fe2848eaebfac5fdf493d26f2
https://doi.org/10.1016/j.revmed.2006.05.019
https://doi.org/10.1016/j.revmed.2006.05.019
Publikováno v:
Annals of the Rheumatic Diseases. 62:540-543
Objective: To study the prevalence of IgA antiphospholipid antibodies, particularly anticardiolipin antibodies (aCL) and anti-β 2 -glycoprotein I (aβ 2 GPI), in a cohort of patients with pregnancy morbidity. Patients and methods: Serum samples from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65db6da75e94e65744ea426d35aec63b
https://doi.org/10.1136/ard.62.6.540
https://doi.org/10.1136/ard.62.6.540
Autor:
Ma. Khamashta, G. R. V. Hughes, Olga Amengual, Tatsuya Atsumi, Francisco J. Tinahones, F I Romero
Publikováno v:
Rheumatology. 37:883-888
SUMMARY The prevalence and clinical significance of antibodies against b 2 -glycoprotein I (anti-b 2 GPI ) and antibodies against oxidized low-density lipoprotein (anti-ox-LDL) were evaluated as potential indicators of arterial disease in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56cc6ea14435e4573e5f18eb8035396d
https://doi.org/10.1093/rheumatology/37.8.883
https://doi.org/10.1093/rheumatology/37.8.883
Autor:
F. Mujic, J. M. Gomez-Zumaquero, M. J. Cuadrado, Eduardo Collantes, Ma. Khamashta, G. R. V. Hughes, Francisco J. Tinahones
Publikováno v:
Rheumatology. 37:746-749
Previous studies have shown a cross-reaction between anticardiolipin and anti-oxidized low-density lipoprotein (LDL) antibodies in patients with the antiphospholipid syndrome (APS). The aim was to investigate the existence of a cross-reaction between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630f47ba63b3f8a419e0ae0908e6b9da
https://doi.org/10.1093/rheumatology/37.7.746
https://doi.org/10.1093/rheumatology/37.7.746
Autor:
Ma. Khamashta, R. I. Fox, Ronald A. Asherson, G. R. V. Hughes, Hong-Ming Fei, Henrique Luiz Staub
Publikováno v:
Annals of the Rheumatic Diseases. 51:495-498
Blood samples from 65 patients with primary Sjögren's syndrome were evaluated for the presence of antiphospholipid antibodies. Increased levels of antiphospholipid antibodies were found in 13 of 65 (20%) of patients. These antiphospholipid antibodie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea748c79d9d80f762e1fb48d02813a5
https://doi.org/10.1136/ard.51.4.495
https://doi.org/10.1136/ard.51.4.495
Publikováno v:
Rheumatology (Oxford, England). 48(4)
There have been significant advances in the treatment of SLE, which have produced major impacts on morbidity and in some cases mortality. The major drugs of the last three decades in treatment of SLE have been corticosteroids, AZA, MTX and cyclophosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509e9d0262f59cea771b6be8b0f33945
https://pubmed.ncbi.nlm.nih.gov/19155279
https://pubmed.ncbi.nlm.nih.gov/19155279
Autor:
David D'Cruz, Ma. Khamashta, Peter C. Taylor, Shirish Sangle, G. R. V. Hughes, Eric Rosenthal
Antiphospholipid (Hughes) syndrome (APS) is a prothrombotic disorder associated with venous and arterial thrombosis. Arterial stenosis, particularly affecting the renal, coeliac and intracerebral arteries, has been observed. Anticoagulation with inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bccf3f5eae81e15a473e280edf52f24f
https://europepmc.org/articles/PMC1798319/
https://europepmc.org/articles/PMC1798319/
Autor:
L. Ferro, Mohammed Yousuf Karim, David D'Cruz, I C Abbs, Muhammad Tungekar, G. R. V. Hughes, C. N. Pisoni, Ma. Khamashta
Publikováno v:
Rheumatology (Oxford, England). 44(10)
INTRODUCTION Lupus membranous nephropathy (LMN) presents a difficult clinical problem as no particular treatment has been proven to be effective. Studies have shown good results with mycophenolate mofetil (MMF) in proliferative lupus nephropathy (LN)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39da186b6262ccd4cee3a3f15e408a1
https://pubmed.ncbi.nlm.nih.gov/16049051
https://pubmed.ncbi.nlm.nih.gov/16049051